In this study, the levels of ST2, BNP, and MCP-1 in the EG were overtly lower than those in the CG (P < 0.05) at week 4 of treatment, indicating that dapagliflozin has an obvious inhibitory effect on myocardial fibrosis in heart failure patients with type 2 diabetes mellitus. The gene discussed is CCL2; the disease is diabetes mellitus.